市場調查報告書
商品編碼
1351090
2030 年家庭輸液治療市場預測 -按產品、給藥途徑、用途、最終用戶和地區進行的全球分析Home Infusion Therapy Market Forecasts to 2030 - Global Analysis By Product, Route of Administration, Application, End Users and By Geography |
根據Stratistics MRC的數據,2023年全球家庭輸液治療市場規模為368.5億美元,預計2030年將達到718.1億美元。
家庭輸液治療涉及患者在家時給藥靜脈或皮下注射藥物給藥生物製劑。此外,進行居家輸液也需要藥物、設備和消耗品。同樣,需要護理服務來教導和教育患者和照護者如何在家中安全地給藥靜脈注射藥物。巡診護理師經常大量參與家庭輸液。護理師通常會教導患者和照護者如何自我給藥,告知他們可能的副作用和治療目標,並定期拜訪他們檢查輸液部位並替換敷料。
根據美國臨床腫瘤學會 (ASCO) 的說法,居家輸液治療有時會帶來風險,需要立即就醫。在這些極為罕見的情況下,與不接受生物治療相關的風險可能超過家庭輸液增加的風險。
家庭輸液治療的關鍵市場促進因素是癌症、糖尿病和心血管疾病等慢性病患病。隨著世界人口老化和慢性病的患病增加,長期治療的需求日益凸顯。居家輸液療法是控制這些疾病並提高患者舒適度和生活品質的實用治療方法。此外,患者和醫療保健專業人員越來越認知到在家中進行複雜治療的好處,正在推動該市場的成長。
家庭輸液治療市場的擴張可能會受到嚴格的法規要求和安全問題的阻礙。維護病人安全需要確保遵守有關設備、藥物處理和感染控制的法律要求。此外,不遵守這些標準而導致的不利事件可能會影響患者對家庭治療的信任和信心。為了緩解這一限制,至關重要的是實施強力的安全措施,同時保持患者自主權和政府監督之間的平衡。
由於遠端醫療平台和遠端監控技術的整合,家庭輸液治療市場具有巨大的商機。這些創新能夠遠端即時監測患者生命徵象、治療進展和副作用。此外,遠端監控患者的能力可以提高安全性,在發生併發症時能夠快速做出反應,為醫療專業人員提供有用的資訊來修改治療計劃,並最終提高患者的安全性,從而改善治療結果。
居家輸液治療越來越依賴科技和數位平台,引發了資料安全和病患隱私方面的問題。網路安全風險可能會影響敏感患者健康資訊的收集、儲存和傳輸。然而,資料安全問題可能會危及患者的隱私,破壞公眾對醫療保健提供者的信任,並引起法律和法規的影響。
家庭輸液治療市場受到 COVID-19 大流行的嚴重影響。雖然醫療保健和供應鏈的早期低迷暫時減緩了服務提供,但由於擔心院內感染,這場大流行最終加速了居家照護的採用。此外,能夠進行遠端監控和諮詢的遠端醫療工具也變得至關重要。這場危機凸顯了家庭輸液療法作為安全替代品的價值,並引發了技術進步、法規環境的變化和醫療保健協調,最終將再形成市場格局並支持以患者為中心的護理,引發了交付方面的進一步創新。
在預測期內,輸液幫浦領域佔據最大的收入佔有率。輸液幫浦領域發揮重要作用,讓患者在家中準確、受控地服用藥物和輸液。這些尖端的醫療技術工具可確保精確的給藥、監測和治療客製化,提高患者安全性、治療效果和整體便利性。此外,輸液幫浦市場同時針對急性和慢性疾病,使醫療保健專業人員能夠充滿信心地進行治療,同時使患者能夠在康復過程中發揮積極作用。
預計特種製藥領域在預測期內的年複合成長率最高。這種成長是由對必須精確給藥、單獨給藥和持續監測的特殊藥物和生物製劑不斷成長的需求所推動的。該部門提供的標靶治療將使患有慢性和複雜疾病的患者受益,包括自體自體免疫疾病、罕見疾病和癌症。此外,藥物研究的進步和家庭給藥的可能性預計將見證市場擴張的顯著成長。
北美地區佔據家庭輸液治療最大的市場。這一優勢得益於該地區完善的醫療基礎設施、技術進步以及居家照護的日益普及。由於人口高齡化、慢性病盛行率的增加以及對以患者為中心的護理的重視,對家庭輸液治療的需求正在增加,特別是在美國和加拿大。此外,有利的政府法規、支付計劃和遠距醫療的引入也促進了北美家庭輸液服務的發展。
亞太地區是預測期間內年複合成長率最高的家庭輸液治療市場。這種顯著的擴張是由於許多變數造成的,包括人們對居家醫療選擇的認知提高、慢性病患病上升以及中國、印度和日本等國家醫療基礎設施的改善。然而,該地區的人口密度和遠端醫療技術的進步推動了家庭輸液療法作為實用且有效的治療選擇的採用。
According to Stratistics MRC, the Global Home Infusion Therapy Market is accounted for $36.85 billion in 2023 and is expected to reach $71.81 billion by 2030 growing at a CAGR of 10% during the forecast period. Home infusion therapy involves giving a patient intravenously or subcutaneously administered medications or biological while they are at home. Moreover, the drug, equipment, and supplies are required to perform a home infusion. Similarly, nursing services are required to instruct and educate the patient and caregivers on how to safely administer infusion drugs at home. Home infusion frequently involves a significant contribution from visiting nurses. Typically, nurses teach patients or caregivers how to self-administer medications, inform them of potential side effects and therapy objectives, and make regular visits to check on the infusion site and change dressings.
According to the American Society of Clinical Oncology (ASCO), home infusion therapy may occasionally provide dangers that necessitate rapid medical attention. In these incredibly rare circumstances, the dangers connected with not having access to biological therapy may exceed the elevated risk of a home infusion.
A significant market driver for home infusion therapy is the rising prevalence of chronic diseases, such as cancer, diabetes, and cardiovascular diseases. A need for long-term treatments arises as the world population ages and the prevalence of chronic diseases increases. A practical treatment for controlling these conditions that also improves the comfort and quality of life of the patient is home infusion therapy. Additionally, the benefits of administering complex treatments at home are understood by both patients and healthcare professionals, which have caused this market to grow.
Home infusion therapy market expansion may be hampered by strict regulatory requirements and safety concerns. Maintaining patient safety requires ensuring compliance with legal requirements for tools, medication handling, and infection control. Furthermore, adverse events that result from not adhering to these standards can affect patient confidence and trust in home-based treatments. To lessen this restriction, it is crucial to implement strong safety measures while maintaining a balance between patient autonomy and governmental oversight.
The market for home infusion therapy has a sizable opportunity due to the integration of telehealth platforms and remote monitoring technology. These innovations allow for remote, real-time monitoring of patient vital signs, treatment development, and adverse reactions. Moreover, the ability to monitor patients remotely improves safety, allows for quick response in the event of complications, and gives medical professionals useful information to modify treatment plans, ultimately leading to better patient outcomes.
Home infusion therapy is becoming more and more dependent on technology and digital platforms, which raises questions about data security and patient privacy. Cybersecurity risks can affect the gathering, storing, and transmission of sensitive patient health information. However, data security issues can jeopardize patient confidentiality, erode public confidence in healthcare providers, and result in legal and regulatory repercussions.
The market for home infusion therapy was significantly impacted by the COVID-19 pandemic. Although the initial hiccups in healthcare and supply chains temporarily slowed down service delivery, the pandemic ultimately accelerated the adoption of home-based care due to concerns about hospital-acquired infections. Moreover, telehealth tools have become essential for enabling remote monitoring and consultations. The crisis highlighted the value of home infusion therapy as a secure substitute, triggering technological advancements, regulatory changes, and healthcare collaborations that ultimately reshaped the market's landscape and sparked additional innovation in patient-centered care delivery.
During the forecasted period, the infusion pumps segment was responsible for the largest revenue share. By providing patients with precise and controlled medication and fluid administration in their own homes, the infusion pump segment plays a crucial role. These cutting-edge medical technology tools guarantee precise dosing, monitoring, and therapy customization, improving patient safety, treatment effectiveness, and general convenience. Moreover, the infusion pump market targets both acute and chronic medical conditions, allowing healthcare professionals to confidently administer therapies while empowering patients to take an active role in their recovery processes.
The segment for specialty pharmaceuticals will have the highest CAGR during the forecast period. This growth can be attributed to the rise in demand for specialty drugs and biologics that need to be administered with accuracy, given to each patient individually, and continuously monitored. The targeted therapies provided by this segment benefit patients with chronic and complex conditions, such as autoimmune disorders, rare diseases, and cancer. Furthermore, due to advances in pharmaceutical research and the potential for home-based administration, there is a huge growth for the market expansion.
The North American region holds the largest market share for home infusion therapy. The region's established healthcare infrastructure, technological advancements, and rising popularity of home-based care options can all be credited with this dominance. Particularly in the United States and Canada, the demand for home infusion therapy has increased as a result of the aging population, the increasing prevalence of chronic diseases, and the focus on patient-centered care. Additionally, the development of home infusion services in North America has also been aided by favourable governmental regulations, payment schemes, and the incorporation of telehealth.
The Asia-Pacific region has the market for home infusion therapy with the highest CAGR during the forecast period. This remarkable expansion is attributed to a number of variables, including the rising awareness of home-based healthcare options, the rise in chronic disease prevalence, and the development of the healthcare infrastructure in nations like China, India, and Japan. However, the adoption of home infusion therapy as a practical and efficient treatment option is being fueled by the area's dense population and advancements in telehealth technology.
Some of the key players in Home Infusion Therapy market include: Option Care Health Inc., Nipro Corporation, Baxter International, Inc., JMS Co., Ltd., Micrel Medical Devices SA, PharMerica, B. Braun Melsungen AG, Terumo Corporation, CVS/Coram , Dickinson and Company, Eitan Medical Ltd , McKesson Medical-Surgical Inc., Smiths Medical. , Caesarea Medical Electronics, BriovaRx/Diplomat (UnitedHealth Optum) , ICU Medical, Inc., CareFusion Corporation, McLaren Health Care, Becton Dickinson and Company and CU Medical, Inc.
In June 2023, Baxter International, an American healthcare company, introduced Progressa+ Next Gen ICU bed for addressing critical needs of patients at their homes. This technology makes it easier for nurses to take care of patients, while supporting therapy at home.
In May 2023, Option Care Health, a healthcare service provider, created an independent platform for home care services in collaboration with Amedisys Inc., a leading provider of home health services. This platform comprises pharmacists, dieticians, therapists, social workers, and others for providing high quality healthcare services at home.
In April 2023, CareFusion, currently owned by Becton Dickinson, an American medical technology company, launched an advanced ultrasound technology to provide clinicians with optimal IV insertions. More than 90% hospitalized patients receive the IV therapy, thus contributing towards the market growth of home infusion therapy.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.